NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Okay, so forget the IT inject patent and others, we'll just stick with this one (so far) as your best proof for your hypothesis ("BCG in use in DCVax-L alleviating issue with immature DC after lysate loading") because it is the only one that talks about BCG and also combining them with WTL, and was before 2003:

http://www.google.com/patents/US20050059151

I'm cool with that, we've found your patent.

Now can you simply prove it's not just IP but actually in use in DCVax L? Because of course if that's what they were using why license the tech from UCLA? Liau flat out stated no dedicated maturational step in making UCLA version of DCVax (which is what they are using in the current P3). Can you find a UCLA patent instead that is from that era that describes DCVax Brain?

Also the areement you found between NWBO and UCLA is interesting but states all the work on trial and design is with UCLA's tech, not NWBO's.

Citing an NWBO patent does not prove what was in the tech they licensed from UCLA.

Also what you think you found on prostate antigen loading + BCG and freeze thaw did not actually deal with issues of freeze thaw necrosed lysate inhibiting maturation of DC for two reasons: 1) there was no lysate used in loading and 2) you seem to have misunderstood the use of their word choice in stating "freeze and then thaw DC" with "freeze thaw cycling." I'm sure that's confusing but they are very different. Freeze thaw cycling literally necrose all cells therein. That's how they expose the lysate to load DC with. You would never freeze thaw cycle DC, otherwise you would destroy them all. You would freeze, and then thaw DC via cryopreservation to preserve, store and /or ship these DC at various time points effectively.

I hope that makes sense.